SEB vs TARS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SEB · Seaboard$3,528.16 ▲ 3.30%
TARS · Tarsus Pharmaceuticals$68.60 ▲ 1.60%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SEB -7.2%
- TARS -5.8%
Head to head
| Metric | SEB | TARS |
|---|---|---|
| Price | $3,528.16 | $68.60 |
| Change today | ▲ 3.30% | ▲ 1.60% |
| Market cap | $3.38B | $3.38B |
| Return, 3 months | -16.7% | +1.2% |
| Return, year to date | -20.5% | -16.2% |
| Return, 1 year | -4.6% | +0.5% |
| P/E (TTM) | 6.1 | – |
| P/B | 0.6 | 32.5 |
| P/E percentile vs own 5y | 7th | 2nd |
| Dividend yield | 0.26% | – |
| Revenue growth (YoY, latest qtr) | +17.8% | +69.4% |
| Net profit growth (YoY) | +48.1% | +8.8% |
| Gross margin | 8.1% | 93.3% |
| Operating margin | 3.4% | -8.0% |
| Net margin | 6.2% | -7.7% |
| Return on equity | 12.3% | -13.7% |
| Analyst target vs. price | – | +46.0% |
| Analyst buy share | – | 100% |
| RSI (14) | 34 | 42 |
| 30-day volatility | 38.8% | 41.6% |
| Max drawdown, 1 year | -42.7% | -32.0% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TARS is the largest of the group by market value.
- TARS has returned the most over the past year.
- TARS is growing revenue fastest.
- SEB keeps the most profit per dollar of sales.
- SEB has been the calmest stock over the last 30 days.